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Reply to: The use of acoustic radiation force-based shear stiffness
in non-alcoholic fatty liver disease
do not require surveillance and monitoring for complications
associated with advanced hepatic ﬁbrosis. We agree with Dr.
Cross that additional statistical analyses are necessary to better
deﬁne the sensitivity, speciﬁcity, negative and positive predictive
values as well as positive and negative likelihood ratios for such a
non-invasive test to have widespread clinical applicability. How-
ever, such analyses would ideally include a much larger sample
size. Therefore, larger studies powered to derive meaningful
threshold values capable of guiding clinical decisions are
necessary.
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Letters to the EditorTo the Editor:
We appreciate the comments and clinical perspectives raised by
Dr. Cross in response to our recent publication concerning the use
of acoustic radiation force-based shear stiffness values in NAFLD
patients to evaluate ﬁbrosis scores [1], and we would like to take
this opportunity to respond to those points. Dr. Cross mentions
the signiﬁcant number of failed stiffness reconstructions in our
study (21.5%), which we agree would be too high for a screening
test to evaluate liver ﬁbrosis. It should be noted that the majority
of those reconstruction failures (84%) occurred in patients with
BMI >30. As discussed in the manuscript [1], higher BMI is
associated with deeper livers, reduced acoustic radiation force
magnitudes, and therefore noisier data for performing the
reconstructions. Many of these patients with failed shear wave
reconstructions did not meet our quality control threshold of
having an IQR/mean60.3 over the replicate shear wave estimates
in the three imaging locations. This reconstruction variability is
an active research efforts focused on improving the next genera-
tion of shear wave reconstruction algorithms. Additionally, we
would recommend restricting the imaging locations utilized in
patients with high BMI to help improve the repeatability of the
reconstructed stiffnesses. While the intercostal imaging windows
tended to yield repeatable shear wave reconstructions, the
addition of the subcostal window was associated with additional
variability in this subset of patients, most likely due to the addi-
tional subcutaneous fat at this location.
Although an intention-to-treat analysis was not performed in
the context of our study, one can argue that knowledge of the
absence of advanced NAFLD (i.e. ﬁbrosis stage 3–4) using a
non-invasive test would decrease resource utilization and cost
associated with performing liver biopsies in all patients with sus-
pected NAFLD. As highlighted in Fig. 2 of the referenced manu-
script [1], the shear modulus across the early stages (ﬁbrosis
stage 0–2) of disease is very narrow, and those patients do not
have increased morbidity or mortality from liver and cardiovas-
cular related outcomes. With the exception of optimizing risk
factors for disease progression, patients with early stage diseaseTransplanted hepatocytes: Wiped out or washed out?
To the Editor:
Hope for the long-term effectiveness of hepatocyte
transplantation (HTx) for metabolic liver disease in pediatric
patients is based on the premise that hepatocytes in the main
constitute a static population, quite unlike for example, the small
bowel where there is constant turnover. However, several recent
studies on the dynamics of hepatocyte turnover raise important
questions about the long-term success of HTx. For example, a
recent lineage tracing study in the mouse has demonstrated that,
within a year, almost the total parenchymal population is
replaced by new hepatocytes differentiating from Sox9-express-
ing interlobular bile ducts [1,2], suggesting that transplanted
hepatocytes will inevitably be ‘washed out’ of the liver within
the turnover time – in about 1 year in the mouse. Other murine
studies have pointed to a small sub-population of biliary duct
cells, also being Sox9-positive, as being bipotential, driving
progenitor cell-mediated liver regeneration [3], seemingly giving
rise to Foxl1-expressing progenitor cells, also with bipotentiality,
but with limited proliferation potential [4]. A further murine
study has shown that 0.076% of all albumin-expressing hepato-
cytes are born from albumin-naïve cells every 4 days in normal
healthy mice, again highlighting the dynamic cell state of the
normal liver [5].
These murine studies have re-awakened the discussion as to
whether hepatocytes ‘stream’ from portal tracts to hepatic veins,
ﬁrst described for the rat liver [6]; subsequently with the liver
being formally proposed as a ‘stem cell and lineage system’, hier-
archically organized into stem, amplifying and differentiating
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